Data Sheet 2_Sustained complete response to TMEp-CI-M platform in refractory small-cell lu

A single-case report details a 60-year-old male with PD-L1-negative extensive-stage small-cell lung cancer and brainstem metastasis. The patient achieved no evidence of disease for over 20 months following treatment with the TMEp-CI-M platform, which integrates stereotactic body radiotherapy, low-dose etoposide, anlotinib, checkpoint inhibition, and microbiome modulation. Authored by Yating Wu and published under CC-BY-4.0 on figshare in June 2026.

Use Cases

• Analyze longitudinal treatment response based on ProGRP biomarker levels mentioned in the description.
• Study the efficacy of multimodal immunotherapy platforms for rare metastatic sites like the brainstem.
• Investigate the role of microbiome modulation in enhancing checkpoint inhibitor therapy outcomes.
• Benchmark survival outcomes for refractory small-cell lung cancer cases against standard-of-care.

Strengths

• Reports a specific clinical outcome of over 20 months of disease-free survival.
• Includes detailed biomarker data, such as ProGRP level normalization from 1803 pg/mL to 23.71 pg/mL.
• Describes a novel, multi-component therapeutic platform (TMEp-CI-M) with potential cross-cancer applicability.

Limitations

• Row count is unknown, which may limit suitability assessment.
• Column-level documentation is absent; field semantics must be inferred after download.
• Data is limited to a single case report, which restricts generalizability.

Provenance

Source

figshare

Collection Method

Clinical case report.

Freshness

Last updated 2026-06-01 05:18:38; freshness should be verified.